---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

---

 

FORM 8-K

 

---

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

August 10, 2004

 

---

 

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

 

---

 

 

Delaware		000-31145		04-3278032
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

 

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

 

(610) 205-2300

(Registrant’s telephone number, including area code)

 

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

---

---

Item 5. Other Events and Required FD Disclosure.

 

On August 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing that it recently completed a Phase II trial of Ramoplanin for the treatment of Clostridium difficile-associated diarrhea (CDAD).

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

		VICURON PHARMACEUTICALS INC.
		(Registrant)
Date: August 11, 2004		By:		/s/ George F. Horner III
				George F. Horner III
				President and Chief Executive Officer